Lipigon Pharmaceuticals AB (9RP) Stock Statistics & Valuation Metrics

Lipigon Pharmaceuticals AB has a market cap or net worth of €323.21K. The enterprise value is -€6.70M.

Lipigon Pharmaceuticals AB has 605,933,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lipigon Pharmaceuticals AB’s return on equity (ROE) is -4.10 and return on invested capital (ROIC) is -401.38%.

The current PE Ratio of Lipigon Pharmaceuticals AB is ―. Lipigon Pharmaceuticals AB’s PEG ratio is 0.00193.

In the last 12 months, Lipigon Pharmaceuticals AB had revenue of 0.00 and earned -32.44M in profits. Earnings per share was -0.08.

In the last 12 months, operating cash flow was -35.77M and capital expenditures -108.00K, giving a free cash flow of -35.88M billion.

Lipigon Pharmaceuticals AB pays an annual dividend of ―, resulting in a dividend yield of ―

Lipigon Pharmaceuticals AB upcoming earnings date is May 20, 2026, Before Open (Not Confirmed).

Lipigon Pharmaceuticals AB as a current ratio of 3.14, with Debt / Equity ratio of 0.00%

In the past 12 months, Lipigon Pharmaceuticals AB has paid 0.00 in taxes.

Lipigon Pharmaceuticals AB EV to EBITDA ratio is 0.21, with an EV/FCF ratio of 0.19.

Lipigon Pharmaceuticals AB has €10.21M in cash and marketable securities with €0.00 in debt, giving a net cash position of €10.21M billion.

Gross margin is -30222.50%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Lipigon Pharmaceuticals AB is ―, which is 11.43% higher than the current price. The consensus rating is ―